Ileostomy Site Carcinoma Literature Review

Anthony Morada

11/11/2020

Table of Contents

## Loading and Cleaning

The table has 29 columns and 116 rows.

## Full-Text Inclusion and Exclusion

Our table contains 94 unique papers

We included 92 patients that were found in 77 unique citations. We excluded 17 citations. Below is reason for full-text exclusions:

## Correspondence Article Duplicate Article Full Text Unavailable   
## 3 1 1   
## Systematic Review Wrong Population   
## 1 11

## Summary of Data

Malignant Etiology = Adenocarcinoma, Lymphoma, Melanoma, Neuroendocrine Tumor, Squamous Cell Carcinoma, Verrucous Carcinoma  
Pre-Malignant Etiology = ESFA, Extramammary Paget Disease

## [1] "<table class=\"Rtable1\">\n<thead>\n<tr>\n<th class='rowlabel firstrow lastrow'></th>\n<th class='firstrow lastrow'><span class='stratlabel'>Overall<br><span class='stratn'>(N=92)</span></span></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Age of Ileostomy Site Malignancy Diagnosis</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>Mean (SD)</td>\n<td>61.9 (12.6)</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Median [Min, Max]</td>\n<td class='lastrow'>61.5 [29.0, 92.0]</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Sex</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>female</td>\n<td>43 (46.7%)</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>male</td>\n<td class='lastrow'>49 (53.3%)</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Race</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>black</td>\n<td>2 (2.2%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>indian</td>\n<td>1 (1.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>white</td>\n<td>13 (14.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Missing</td>\n<td class='lastrow'>76 (82.6%)</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Age of Stoma</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>Mean (SD)</td>\n<td>30.2 (13.0)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Median [Min, Max]</td>\n<td>31.0 [0.500, 63.0]</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Missing</td>\n<td class='lastrow'>4 (4.3%)</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Pathology</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>Adenocarcinoma</td>\n<td>70 (76.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>ESFA</td>\n<td>2 (2.2%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Extramammary Paget Disease</td>\n<td>1 (1.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Lymphoma</td>\n<td>3 (3.3%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Melanoma</td>\n<td>3 (3.3%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Neuroendocrine Tumor</td>\n<td>1 (1.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Squamous Cell Carcinoma</td>\n<td>11 (12.0%)</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Verrucous Carcinoma</td>\n<td class='lastrow'>1 (1.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Pathology Potential</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>Malignant</td>\n<td>89 (96.7%)</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Pre-malignant</td>\n<td class='lastrow'>3 (3.3%)</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Index Surgery Indication</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>Behcet's Disease</td>\n<td>1 (1.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Crohn's Disease</td>\n<td>5 (5.4%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>FAP</td>\n<td>18 (19.6%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Hirschsprung Disease with Colectomy</td>\n<td>1 (1.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Rectal Adenocarcinoma</td>\n<td>2 (2.2%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Ulcerative Colitis</td>\n<td>64 (69.6%)</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Urothelial Transitional Cell Carcinoma</td>\n<td class='lastrow'>1 (1.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Generalized Surgery Indication</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>FAP</td>\n<td>18 (19.6%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>IBD</td>\n<td>69 (75.0%)</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Other</td>\n<td class='lastrow'>5 (5.4%)</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Follow Up (Years)</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>Mean (SD)</td>\n<td>2.05 (2.25)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Median [Min, Max]</td>\n<td>1.00 [0.0830, 11.0]</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Missing</td>\n<td class='lastrow'>31 (33.7%)</td>\n</tr>\n<tr>\n<td class='rowlabel firstrow'><span class='varlabel'>Follow Up Status</span></td>\n<td class='firstrow'></td>\n</tr>\n<tr>\n<td class='rowlabel'>Alive</td>\n<td>57 (62.0%)</td>\n</tr>\n<tr>\n<td class='rowlabel'>Dead</td>\n<td>13 (14.1%)</td>\n</tr>\n<tr>\n<td class='rowlabel lastrow'>Missing</td>\n<td class='lastrow'>22 (23.9%)</td>\n</tr>\n</tbody>\n</table>\n"

### Pre-Malignant vs Malignant

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| label | levels | Malignant | Pre-malignant | p |
| Age of Ileostomy Site Malignancy Diagnosis | Mean (SD) | 62.1 (12.7) | 55.0 (6.0) | 0.339 |
| Sex | female | 41 (46.1) | 2 (66.7) | 0.908 |
|  | male | 48 (53.9) | 1 (33.3) |  |
| Race | black | 2 (14.3) |  | 0.768 |
|  | indian | 1 (7.1) |  |  |
|  | white | 11 (78.6) | 2 (100.0) |  |
| Age of Stoma | Mean (SD) | 30.5 (13.1) | 22.0 (10.1) | 0.270 |
| Pathology | Adenocarcinoma | 70 (78.7) |  | <0.001 |
|  | Lymphoma | 3 (3.4) |  |  |
|  | Melanoma | 3 (3.4) |  |  |
|  | Neuroendocrine Tumor | 1 (1.1) |  |  |
|  | Squamous Cell Carcinoma | 11 (12.4) |  |  |
|  | Verrucous Carcinoma | 1 (1.1) |  |  |
|  | ESFA |  | 2 (66.7) |  |
|  | Extramammary Paget Disease |  | 1 (33.3) |  |
| Index Surgery Indication | Behcet’s Disease | 1 (1.1) |  | 0.996 |
|  | Crohn’s Disease | 5 (5.6) |  |  |
|  | FAP | 17 (19.1) | 1 (33.3) |  |
|  | Hirschsprung Disease with Colectomy | 1 (1.1) |  |  |
|  | Rectal Adenocarcinoma | 2 (2.2) |  |  |
|  | Ulcerative Colitis | 62 (69.7) | 2 (66.7) |  |
|  | Urothelial Transitional Cell Carcinoma | 1 (1.1) |  |  |
| Generalized Surgery Indication | FAP | 17 (19.1) | 1 (33.3) | 0.780 |
|  | IBD | 67 (75.3) | 2 (66.7) |  |
|  | Other | 5 (5.6) |  |  |

### Adenocarcinoma vs Squamous

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| label | levels | Adenocarcinoma | Squamous Cell Carcinoma | p |
| Age of Ileostomy Site Malignancy Diagnosis | Mean (SD) | 59.4 (12.0) | 71.8 (5.7) | 0.001 |
| Sex | female | 34 (48.6) | 4 (36.4) | 0.668 |
|  | male | 36 (51.4) | 7 (63.6) |  |
| Race | black | 2 (16.7) |  | 0.727 |
|  | indian | 1 (8.3) |  |  |
|  | white | 9 (75.0) | 2 (100.0) |  |
| Age of Stoma | Mean (SD) | 29.6 (11.4) | 38.1 (14.1) | 0.030 |
| Index Surgery Indication | Crohn’s Disease | 3 (4.3) | 1 (9.1) | 0.013 |
|  | FAP | 17 (24.3) |  |  |
|  | Hirschsprung Disease with Colectomy | 1 (1.4) |  |  |
|  | Rectal Adenocarcinoma | 1 (1.4) |  |  |
|  | Ulcerative Colitis | 48 (68.6) | 8 (72.7) |  |
|  | Behcet’s Disease |  | 1 (9.1) |  |
|  | Urothelial Transitional Cell Carcinoma |  | 1 (9.1) |  |
| Generalized Surgery Indication | FAP | 17 (24.3) |  | 0.026 |
|  | IBD | 51 (72.9) | 9 (81.8) |  |
|  | Other | 2 (2.9) | 2 (18.2) |  |

### FAP vs IBD

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| label | levels | FAP | IBD | Other | p |
| Age of Ileostomy Site Malignancy Diagnosis | Mean (SD) | 57.2 (12.4) | 63.4 (12.0) | 57.0 (18.5) | 0.117 |
| Sex | female | 8 (44.4) | 34 (49.3) | 1 (20.0) | 0.438 |
|  | male | 10 (55.6) | 35 (50.7) | 4 (80.0) |  |
| Race | black | 2 (28.6) |  |  | 0.001 |
|  | white | 5 (71.4) | 8 (100.0) |  |  |
|  | indian |  |  | 1 (100.0) |  |
| Age of Stoma | Mean (SD) | 26.2 (8.4) | 32.2 (13.0) | 14.5 (13.9) | 0.005 |
| Pathology | Adenocarcinoma | 17 (94.4) | 51 (73.9) | 2 (40.0) | 0.012 |
|  | ESFA | 1 (5.6) | 1 (1.4) |  |  |
|  | Extramammary Paget Disease |  | 1 (1.4) |  |  |
|  | Lymphoma |  | 3 (4.3) |  |  |
|  | Melanoma |  | 3 (4.3) |  |  |
|  | Neuroendocrine Tumor |  | 1 (1.4) |  |  |
|  | Squamous Cell Carcinoma |  | 9 (13.0) | 2 (40.0) |  |
|  | Verrucous Carcinoma |  |  | 1 (20.0) |  |
| Pathology Potential | Malignant | 17 (94.4) | 67 (97.1) | 5 (100.0) | 0.780 |
|  | Pre-malignant | 1 (5.6) | 2 (2.9) | 0 (0.0) |  |
| Index Surgery Indication | FAP | 18 (100.0) |  |  | <0.001 |
|  | Crohn’s Disease |  | 5 (7.2) |  |  |
|  | Ulcerative Colitis |  | 64 (92.8) |  |  |
|  | Behcet’s Disease |  |  | 1 (20.0) |  |
|  | Hirschsprung Disease with Colectomy |  |  | 1 (20.0) |  |
|  | Rectal Adenocarcinoma |  |  | 2 (40.0) |  |
|  | Urothelial Transitional Cell Carcinoma |  |  | 1 (20.0) |  |